Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

Severe Sepsis or Septic Shock Clinical Trial

Official title:
Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis

Status Completed

Clinical Trial Summary

Observational studies among critically ill patients have shown strong associations between vitamin D deficiency and adverse outcomes, including increased length of stay, infection, and mortality. It is unknown whether vitamin D deficiency contributes directly to adverse outcomes or whether it is simply a biomarker of severity of illness or overall health status. However, vitamin D plays a key role in host defense, largely by stimulating production of the anti-microbial peptide cathelicidin (LL-37). We will test the hypothesis that administration of activated vitamin D (calcitriol) will increase serum levels of cathelicidin.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01689441
Study type	Interventional
Source	Brigham and Women's Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	February 2013
Completion date	February 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03682003` - Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?
Recruiting	`NCT03068741` - Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)	Phase 4
Completed	`NCT01845766` - Effects of Early Exercise Rehabilitation on Long-term Functional Recovery in Patients With Severe Sepsis	N/A
Completed	`NCT02656654` - COrporeal Compression at the ONset of Severe Sepsis and Septic Shock	N/A